Visioneering Technologies is stepping up efforts to broaden its profile both geographically and through new product reach with the appointment of Kuang-mon (Ashley) Tuan, OD, PhD, FAAO, as Chief Medical Officer.
The US-based medical device company and producer of the NaturalVue Multifocal 1 Day Contact Lenses said Dr Tuan will be responsible for managing clinical research studies, such as Project PROTECT, the NaturalVue (etafilcon A) multifocal randomised clinical trial for myopia progression control in children, helping identify and develop new products, and leading efforts to communicate findings in key journals and scientific meetings.
Her impressive career history supports our goal to seek out leaders in our industry to help VTI continue to expand and thrive through innovation in areas such as myopia, and other challenging vision areas
Dr Tuan will also lead VTI’s Professional Services team as it communicates technical information on products and initiatives to eye care professionals.
Dr Ashley Tuan
“We are extremely proud to introduce Dr Tuan to the Asia Pacific market. Her impressive career history supports our goal to seek out leaders in our industry to help VTI continue to expand and thrive through innovation in areas such as myopia, and other challenging vision areas,” said Visioneering’s CFO, Brian Lane. “We are proud to have Dr Tuan join our team and look forward to the many contributions she will make to our organisation as we seek to broaden our profile both geographically and through new product reach.”
Dr Tuan’s professional career encompasses 27 years’ experience and includes a strong background in clinical and vision research in areas such as myopia, higher order aberrations, presbyopia, refractive surgeries and age-related macular degeneration. Most recently, as Vice-President of Mojo Vision, a smart contact lens company, Dr Tuan focused on medical use cases and contact lens platform product strategy, and contact lens system research and development with oversight of clinical, regulatory, medical and professional affairs. While at CooperVision, Dr Tuan was part of the team that delivered the three-year study that enabled the launch of myopia control contact lenses, MiSight.
Dr Tuan is a member of the Association for Research in Vision and Ophthalmology (ARVO), the British Contact Lens Association (BCLA) and is a Fellow of the American Academy of Optometry (FAAO). She obtained her Masters degree in Physiological Optics, her Doctor of Optometry degree from The Ohio State University, and her PhD in Vision Science from the University of California at Berkeley.
“I am thrilled to be joining VTI and returning to the field of myopia management. My career has been focused on translating research and technology to advancing various sectors of vision care,” said Dr Tuan. “The vision care industry is entering a new evolution phase of complex and a fascinating period of growth. Together with the VTI team, I am looking forward to the exciting journey of defining an ecosystem and delivering solutions for the Vision Care community with the goal of reducing the risk of myopia-related visual impairment globally.”
To contact Dr Tuan directly email [email protected].
